Last reviewed · How we verify
Fluzone Quadrivalent
At a glance
| Generic name | Fluzone Quadrivalent |
|---|---|
| Also known as | IIV4 inactivated influenza vaccine, IIV4, Influenza vaccination, F-QIV |
| Sponsor | Fatimah Dawood |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Opioid, HIV and Immune System (PHASE4)
- BPL-1357 Against H1N1 Influenza Virus Challenge (PHASE2)
- Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants (PHASE3)
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza (PHASE1)
- Addressing Unfunded Vaccines Through a Co-payment Mechanism in Pharmacies (NA)
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluzone Quadrivalent CI brief — competitive landscape report
- Fluzone Quadrivalent updates RSS · CI watch RSS
- Fatimah Dawood portfolio CI